Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Bitcoin Trust — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while iShares Bitcoin Trust trades at $35.63. Which is the better fit depends on your goals.
| ALNY | IBIT | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Crypto-linked |
52-Week High | $491.22 | $71.29 |
52-Week Low | $278.09 | $33.29 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IBIT trades at $36.23, up 1.17% today, with neutral technical signals from moving averages and oscillators. Support and resistance cluster around $35-$36. The stock's financial ratios are unavailable, but recent news highlights its position as a leading spot Bitcoin ETF with $44.9 billion in assets under management as of June 2026, per The Motley Fool.
Outlook remains tied to Bitcoin ETF flows and investor sentiment toward crypto-linked equities. Risks include market volatility and competitive pressure from other ETFs. Institutional interest is strong, but performance depends heavily on broader cryptocurrency trends and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
